Kuano secures £1M from ACF Investors, o2h Ventures and a syndicate of Cambridge-based angel investors.

Kuano, a London, UK-based developer of a software platform for rapid, cost effective quantum modelling of enzymes, announced raising £1M ($1.4M) in capital funding.

The money was raised from UK-based investors, including ACF Investors, o2h Ventures and a syndicate of Cambridge-based angel investors.

The funding will accelerate the company’s growth as it moves further towards commercialisation.

Kuano, founded in 2020 by David Wright, Jarryl D'Oyley, Parminder Ruprah and CEO  Vid Stojevic, combines quantum physics, artificial intelligence (AI) and medicinal chemistry in a unique approach to transforming the discovery of therapeutics focused on enzyme inhibition. Enzymes represent the largest class of drug targets, with over USD40 billion of pharmaceutical sales attributable to small molecule inhibitors of enzymes.

Kuano is using its platform to advance its own pipeline of novel therapeutics targeting unmet medical needs, as well as in collaborative programs with leading academic and commercial partners. This includes a recent research collaboration with Alzheimer’s Research UK University College London Drug Discovery Institute to identify inhibitors for treating degenerative neurological disorders.